Cancer immunotherapy

Merck Announces Phase 3 KEYNOTE-355 Trial Met Primary Endpoint of Overall Survival (OS) in Patients with Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed PD-L1 (CPS ≥10)

Tuesday, July 27, 2021 - 11:45am

These new overall survival results confirm that KEYTRUDA in combination with chemotherapy represents an important treatment option for certain patients with metastatic TNBC.

Key Points: 
  • These new overall survival results confirm that KEYTRUDA in combination with chemotherapy represents an important treatment option for certain patients with metastatic TNBC.
  • The safety and effectiveness of KEYTRUDA in pediatric patients with MSI-H central nervous system cancers have not been established.
  • KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
  • KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).

FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Single Agent as Adjuvant Treatment After Surgery

Tuesday, July 27, 2021 - 11:30am

KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

Key Points: 
  • KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
  • KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).
  • KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of patients with advanced renal cell carcinoma.
  • KEYTRUDA is indicated for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.

Agenus to Provide Corporate Update and Second Quarter 2021 Financial Report

Monday, July 26, 2021 - 9:05pm

LEXINGTON, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that it will release its second quarter 2021 financial results before the market opens on Monday, August 9, 2021.

Key Points: 
  • LEXINGTON, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that it will release its second quarter 2021 financial results before the market opens on Monday, August 9, 2021.
  • Agenus executives will host a conference call and webcast at 8:30 a.m.
  • ET the same day to discuss the results and to provide a corporate update.
  • Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer.

F-star Therapeutics Provides Interim Update on SB 11285 First-In-Human Dose-Escalation Study in Patients with Advanced Solid Tumors

Monday, July 26, 2021 - 1:00pm

The ongoing multicenter clinical trial ( NCT04096638 ) is evaluating the safety and efficacy of intravenously (IV) administered SB 11285 alone and in combination with the anti-PD-L1 monoclonal antibody, atezolizumab, in patients with advanced solid tumors.

Key Points: 
  • The ongoing multicenter clinical trial ( NCT04096638 ) is evaluating the safety and efficacy of intravenously (IV) administered SB 11285 alone and in combination with the anti-PD-L1 monoclonal antibody, atezolizumab, in patients with advanced solid tumors.
  • In clinical trials, the first generation of these compounds were typically injected intratumorally in patients with solid cancers.
  • F-stars SB 11285 is differentiated from the first generation of STING agonists, as it is delivered systemically, enabling access to hard-to-reach tumors.
  • Additionally, SB 11285 may facilitate migration of newly activated immune cells from the periphery into the tumor site.

Checkpoint Inhibitor Refractory Cancer Epidemiology Research Report 2021-2030 - ResearchAndMarkets.com

Monday, July 26, 2021 - 10:43am

The "Checkpoint Inhibitor Refractory Cancer - Epidemiology Forecast 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Checkpoint Inhibitor Refractory Cancer - Epidemiology Forecast 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This 'Checkpoint-inhibitor Refractory Cancer - Epidemiology Forecast - 2030' report delivers an in-depth understanding of Checkpoint-inhibitor Refractory Cancer, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • The Checkpoint-inhibitor Refractory Cancer epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries.
  • The disease epidemiology covered in the report provides historical as well as forecasted Checkpoint-inhibitor Refractory Cancer symptoms epidemiology segmented as the Incidence by tumor type, Checkpoint-inhibitor-treated patients and Checkpoint-inhibitor refractory patients.

PD-1 Resistant Head and Neck Cancer (HNC) Epidemiology Forecast Report 2021-2030 - ResearchAndMarkets.com

Monday, July 26, 2021 - 10:37am

This 'PD-1 Resistant Head and Neck Cancer - Epidemiology Forecast - 2030' report deliver an in-depth understanding of and historical and forecasted epidemiology of PD-1 Resistant Head and Neck Cancer in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), Japan, China, South Korea, and Taiwan.

Key Points: 
  • This 'PD-1 Resistant Head and Neck Cancer - Epidemiology Forecast - 2030' report deliver an in-depth understanding of and historical and forecasted epidemiology of PD-1 Resistant Head and Neck Cancer in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), Japan, China, South Korea, and Taiwan.
  • The disease epidemiology covered in the report provides historical as well as forecasted PD-1 Resistant Head and Neck Cancer symptoms epidemiology segmented as the Head and Neck Cancer diagnoses patients, PD-1 treated patients and PD-1 refractory patients.
  • The report provides the PD-1 Resistant Head and Neck Cancer epidemiology segmentation by Head and Neck cancer diagnosed patients in 7MM, China, South Korea and Taiwan.
  • The report provides the PD-1 Resistant Head and Neck Cancer epidemiology segmentation by PD-1 treated patients in 7MM, China, South Korea and Taiwan.

OncoSec to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference

Monday, July 26, 2021 - 1:30pm

PENNINGTON, N.J. and SAN DIEGO, July 26, 2021 /PRNewswire/ --OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that Interim CEO and Chief Operating Officer, Brian Leuthner, and Senior Vice President, Chief Clinical Development Officer, Sandra Aung, Ph.D., will participate in a fireside chat at the BTIG Virtual Biotechnology Conference being held Monday, August, 9th Tuesday, August 10th, 2021.

Key Points: 
  • PENNINGTON, N.J. and SAN DIEGO, July 26, 2021 /PRNewswire/ --OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that Interim CEO and Chief Operating Officer, Brian Leuthner, and Senior Vice President, Chief Clinical Development Officer, Sandra Aung, Ph.D., will participate in a fireside chat at the BTIG Virtual Biotechnology Conference being held Monday, August, 9th Tuesday, August 10th, 2021.
  • For those not attending, a replay of the presentation will be available until the end of the conference on the BTIG conference website.
  • Must be a BTIG client to attend and access the replay.
  • OncoSec Medical Incorporated (the "Company," "OncoSec," "we" or "our") is a biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer.

Eisai: FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma

Friday, July 23, 2021 - 1:17am

Based on the type and/or severity of the adverse reaction, LENVIMA may be interrupted, reduced and/or discontinued.

Key Points: 
  • Based on the type and/or severity of the adverse reaction, LENVIMA may be interrupted, reduced and/or discontinued.
  • Based on its mechanism of action and data from animal reproduction studies, LENVIMA can cause fetal harm when administered to a pregnant woman.
  • Based on the severity of the adverse reaction, KEYTRUDA should be withheld or permanently discontinued and corticosteroids administered if appropriate.
  • "Based on Phase 3 data, today's approval acts as the confirmatory trial to our previous accelerated approval of KEYTRUDA plus LENVIMA in patients with certain types of advanced endometrial cancer and reinforces the impact of our joint research with Eisai in exploring the potential of this combination to treat more patients with challenging types of cancer."

Ribon Therapeutics Announces Publication in Cancer Cell of Pre-Clinical and Mechanism of Action Data for RBN-2397

Thursday, July 22, 2021 - 6:00pm

Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced the first publication in the peer-reviewed journal, Cancer Cell, of preclinical data from its lead asset, RBN-2397, a small molecule inhibitor of PARP7.

Key Points: 
  • Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced the first publication in the peer-reviewed journal, Cancer Cell, of preclinical data from its lead asset, RBN-2397, a small molecule inhibitor of PARP7.
  • PARP7 is overexpressed in a number of tumors, including squamous cell carcinoma of the lung (SCCL), which represents approximately 30% of all non-small cell lung cancers.
  • PARP7 is the first monoPARP to be targeted therapeutically and RBN-2397 is the first potent and selective PARP7 inhibitor to enter clinical development.
  • Ribon Therapeutics is a clinical stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease.

LIXTE BIOTECHNOLOGY COMMENTS ON REPORT THAT ITS PP2A INHIBITOR LB-100 COMBINED WITH ANOTHER INVESTIGATIONAL AGENT STIMULATES BONE GROWTH IN MODELS OF DWARFISM

Thursday, July 22, 2021 - 2:25pm

LB-100 has been shown to enhance anti-cancer activity of standard chemotherapy and immunotherapy regimens against a broad spectrum of human cancers in animal models.

Key Points: 
  • LB-100 has been shown to enhance anti-cancer activity of standard chemotherapy and immunotherapy regimens against a broad spectrum of human cancers in animal models.
  • Our focus is to demonstrate the clinical therapeutic benefit of LB-100 in one or more cancers for which more effective treatments are urgently needed.
  • A major driver of cancer is defects in the switches that turn the biochemical pathways in cells on and off.
  • This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at sec.gov/edgar.shtml .